NanoViricides (OTC:NNVC) reported on Monday that its president Anil Diwan will present at the 10th Annual NanoBusiness Conference and NanoManufacturing Summit.
The conference, which is being held at the Seaport World Trade Centre in Boston, is expected to take place around 2 p.m. to 4 p.m.
Diwan has been invited to participate in the panel on Nanomedicine and Nanodiagnostics. Moreover, he will present a summary of the NanoViricides platform technology, the company’s drug pipeline, along with its progress toward initial U.S. FDA submission.
NanoViricides is a development stage company that is creating special purpose nanomaterials for viral therapy.
The company is developing drugs against a number of viral diseases including H1N1 swine flu, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Dengue fever, Hepatitis C, Rabies, and Ebola virus, among others.
Recently, NanoViricides said that it is working on enabling current good manufacturing practices (cGMP) capability to produce its drug candidates. The cGMP process is required when NanoViricides is ready to file an Investigational New Drug application to the FDA.
Additionally, the company said that it has chosen NV-INF-1 in its anti-influenza drug program FluCide to develop for a regulatory submission both domestically and internationally.
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment